Article
Genetic Predictors of Response to Zolbetuximab in Gastric Adenocarcinoma
2026-01-01
Abstract excerpt
<h4>Background: </h4> /Objectives: The anti-CLDN18.2 antibody zolbetuximab has emerged as a novel therapeutic option for advanced gastric adenocarcinoma. However, robust predictive biomarkers for its efficacy remain an unmet need. <h4>Methods:</h4> Utilizing the Japanese Center for Cancer Genomics and Advanced Therapeutics database, we retrospectively analyzed the clinical and genomic profiles of 49 patients with...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- aff9440b-0e2f-5caa-9b65-7c39aa1ebafc
- DOI
- 10.20944/preprints202601.0008.v1
